Cipla has reported results for the fourth quarter and year ended March 31, 2020.
The Company has reported a fall of 4.65% in its net profit at Rs 604.57 crore for the quarter under review as compared to Rs 634.07 crore for the same quarter in the previous year. Total income of the company decreased by 0.11% at Rs 3546.85 crore for Q4FY20 as compared Rs 3550.92 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 33.02% in its net profit for the period attributable to shareholders of the company at Rs 245.95 crore for the quarter under review as compared to Rs 367.20 crore for the same quarter in the previous year. Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20 as compared Rs 4499.34 crore for the corresponding quarter previous year.
For the year ended March 31, 2020, the company has reported a rise of 22.76% in its net profit at Rs 2318.17 crore as compared to Rs 1888.41 crore for the previous year. Total income of the company increased by 4.64% at Rs 13552.00 crore for year under review as compared to Rs 12951.53 crore for year ended March 31, 2019.
For the year ended March 31, 2020, on the consolidated basis, the company has reported a rise of 1.23% in its net profit for the period attributable to shareholders of the company at Rs 1546.52 crore as compared to Rs 1527.70 crore for the previous year. Total income of the company increased by 3.78% at Rs 17476.19 crore for year under review as compared to Rs 16838.98 crore for year ended March 31, 2019.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.10 |
| Dr. Reddys Lab | 1286.90 |
| Cipla | 1337.95 |
| Zydus Lifesciences | 901.10 |
| Lupin | 2348.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: